Company Presentation
NMD Pharma company information, funding & investors | Dealroom.co
Company Presentation
Tunge pengetanke klar til nye investeringer i biotekselskab fra Aarhus
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma ApS Annual Report for 1 January - 31 December 2017
Investors — NMD Pharma
Management — NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Management — NMD Pharma
NMD Pharma - Inkef capital
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma company information, funding & investors | Dealroom.co
Management — NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Management — NMD Pharma
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma
